Articles

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

Collaborative Group on Hormonal Factors in Breast Cancer*

Summary

Background The Collaborative Group on Hormonal Factors in Breast Cancer has brought together and reanalysed the worldwide epidemiological evidence on the relation between breast cancer risk and use of hormonal contraceptives.

Methods Individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 studies conducted in 25 countries were collected, checked, and analysed centrally. Estimates of the relative risk for breast cancer were obtained by a modification of the Mantel-Haenszel method. All analyses were stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born, and the age she was when her risk of conception ceased.

Findings The results provide strong evidence for two main conclusions. First, while women are taking combined oral contraceptives and in the 10 years after stopping there is a small increase in the relative risk of having breast cancer diagnosed (relative risk [95% CI] in current users 1.24 [1.15-1.33], 2p<0.00001; 1-4 years after stopping 1.16 [1.08-1.23], 2p=0.00001; 5-9 years after stopping 1.07 [1.02-1.13], 2p=0.009). Second, there is no significant excess risk of having breast cancer diagnosed 10 or more years after stopping use (relative risk 1.01 [0.96-1.05], NS). The cancers diagnosed in women who had used combined oral contraceptives were less advanced clinically than those diagnosed in women who had never used these contraceptives: for ever-users compared with never-users, the relative risk for tumours that had spread beyond the breast compared with localised tumours was 0.88 (0.81-0.95; 2p=0.002). There was no pronounced variation in the results for recency of use between women with different background risks of breast cancer, including women from different countries and ethnic groups, women with different reproductive histories, and those with or without a family history of breast cancer. The studies included in this collaboration represent about 90% of the epidemiological information on the topic, and what is known about the other studies suggests that their omission has not materially affected the main conclusions.

*Collaborators listed at end of article

Correspondence to: Secretariat, Collaborative Group on Hormonal Factors in Breast Cancer, ICRF Cancer Epidemiology Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK

Other features of hormonal contraceptive use such as duration of use, age at first use, and the dose and type of hormone within the contraceptives had little additional effect on breast cancer risk, once recency of use had been taken into account. Women who began use before age 20 had higher relative risks of having breast cancer diagnosed while they were using combined oral contraceptives and in the 5 years after stopping than women who began use at older ages, but the higher relative risks apply at ages when breast cancer is rare and, for a given duration of use, earlier use does not result in more cancers being diagnosed than use beginning at older ages.

Because breast cancer incidence rises steeply with age, the estimated excess number of cancers diagnosed in the period between starting use and 10 years after stopping increases with age at last use: for example, among 10 000 women from Europe or North America who used oral contraceptives from age 16 to 19, from age 20 to 24, and from age 25 to 29, respectively, the estimated excess number of cancers diagnosed up to 10 years after stopping use is 0.5 (95% Cl 0.3–0.7), 1.5 (0.7–2.3), and 4.7 (2.7–6.7). Up to 20 years after cessation of use the difference between ever-users and never-users is not so much in the total number of cancers diagnosed, but in their clinical presentation, with the breast cancers diagnosed in ever-users being less advanced clinically than those diagnosed in never-users.

The relation observed between breast cancer risk and hormone exposure is unusual, and it is not possible to infer from these data whether it is due to an earlier diagnosis of breast cancer in ever-users, the biological effects of hormonal contraceptives, or a combination of reasons.

Interpretation Women who are currently using combined oral contraceptives or have used them in the past 10 years are at a slightly increased risk of having breast cancer diagnosed, although the additional cancers diagnosed tend to be localised to the breast. There is no evidence of an increase in the risk of having breast cancer diagnosed 10 or more years after cessation of use, and the cancers diagnosed then are less advanced clinically than the cancers diagnosed in never-users.

Lancet 1996; 347: 1713-27

See Editorial page 1707

Introduction

The use of female sex hormones as contraceptives began in 1960, since when an estimated 200 million women

Other ^{5,11,14,16} All prospective studies CASE_CNTROL STUI 1976 Brinton ³⁴ 1980 Bernstein/Pike 1981 Histop ⁸ 1983 UKNational ²⁵ 1983 Bain/Sikind ²⁷ 1983 Bain/Sikind ²⁷ 1983 Bain/Sikind ²⁷ 1984 Meirik/Lund ⁹ 1985 YuYuan/Wan 1986 Rookus/Nate 1988 4StateStudy ⁴⁵ 1988 AStateStudy ⁴⁵ 1988 Promic-Zakelj ⁶ 1989 Yang/Gallagh 1989 Yang/Gallagh 1980 Vithe ² 10:12:172 All case-control studie population control CASE-CVTROL STUDI 1980 1980 Vessey ^{4,13} 1981 Ravnihar ¹⁸ 1983 WHO (develop WHO (develop WHO (develop 1986 Clavel ³¹ 1987 LaVeccha ⁴⁵		Ever	Ontraceptive Lise	Cter	Intica	Relative risk of	
PROSPECTIVE STUDI 1980 RCGP ¹⁵ 1982 Oxford/FPA ²⁶ 1985 NursesHealth 1987 AmerCancSo 1988 Natherlands C Other ^{5,1114,10} Other ^{5,1114,10} All prospective studier CASE-CONTROL STUI 1976 Brinton ³⁴ 1980 Bernstein/Plki 1981 Histop ⁸ 1983 Baln/Siskind ²² 1983 Baln/Siskind ²² 1983 Ewertz ³⁵ 1984 Long Island ³³ 1985 Yu'Yuan/Wan 1986 Yang/Gallegh 1989 Primic-Zakelj ⁴ 1989 Yang/Gallegh 1980 Vessey ^{4,13} 1981 Rawinhar ¹⁸ 1983 WHO (develop WHO (develop WHO (develop WHO (develop WHO (develop 1987 LaVecchla ⁴⁵	ale Study	Cases/Controls	Cases/Controls	(O-E)	ver(O-E)	In ever-Users vers RR* & 99% CI	RR*±SD
1980 RCGP ¹⁵ 1982 Oxford/FPA ²⁶ 1985 NursesHealth 1985 CanadianNBS 1987 AmerCaneSo 1988 Netherlands C Other ^{8,11,14,16} Other ^{8,11,14,16} All prospective studies CASE-CONTROL STUD 1988 Brinton ³⁴ 1980 Bernstein/Pike 1981 Histop ⁸ 1983 UKNational ²⁵ 1984 Clarke ³⁸ 1985 Yu/Yuan/Wan 1986 AstateStudy ⁴⁷ 1988 Rookus/van L 1989 Yang/Gallagh 1989 Primic-Zakelj ⁵⁰ 1989 Yang/Gallagh 1980 Vessey ⁴¹³ 1981 Rawinkar ¹⁸ 1983 WHO (develop WHO (develop WHO (develop WHO (develop 1987 LaVecchla ⁴⁵						1:	
1982 Oxford/FPA ²⁶ 1985 NursesHealth 1985 CanadianNES 1987 AmerCancSor 1988 Netherlands C Other ^{3,1114,10} Other ^{3,1114,10} All prospective studies CASE-CONTROL STUI 1976 Brinton ³⁴ 1980 Bernstein/Pike 1981 CASH ³⁴ 1983 Bain/Siskind ²² 1984 Long Island ³⁵ 1984 Long Island ³⁵ 1985 Yu/Yuan/Wan 1986 Rookus/van L 1987 Daling ⁵⁰ 1988 AStateStudy ⁴⁷ 1989 Yang/Gallagh 1989 Yang/Gallagh 1989 Yang/Gallagh 1989 Yang/Gallagh 1980 Vessey ^{4,13} 1981 Rawnihar ¹⁸ 1983 WHO (develop WHO (develop WHO (develop 1987 LaVechla ⁴⁵ 1987 LaVechla ⁴⁵			100				
1985 NursesHealth 1985 CanadianNBS 1987 AmerCaneSor 1988 Netherlands C Other ^{8-1114,10} Other ^{8-1114,10} All prospective studies CASE-CONTROL STUI 1976 Brinton ³⁴ 1980 Bernstein/Pike 1981 CASE-3 1983 UKNational ²⁵ 1984 Clarko ³⁸ 1985 Paul/Skegg ²⁸ 1986 Clarko ³⁹ 1987 Daling ⁵⁰ 1988 4StateStudy ⁴⁷ 1989 Yang/Gallagh 1989 Yang/Gallagh 1989 Yang/Gallagh 1980 Vessey ^{4,13} 1981 Rawnik-I ⁸ 1983 WHO (develop WHO (develop 1986 Clavel ³¹ 1987 LaVecela ³¹		198/728	128/576	13 0	55 6	H	1 26±0 151
1985 CanadianNBS 1987 AmerCancSo 1988 Netherlands C Other ^{5,11,14,10} Other ^{5,11,14,10} All prospective studiet CASE-CONTROL STUI 1976 Brinton ³⁴ 1980 Bernstein/Pike 1981 Histop ⁸ 1983 UKNational ²⁵ 1984 CaSH ³⁴ 1983 Bain/Siskind ²² 1984 Long Island ³³ 1985 Yu/Yuan/Wan 1988 Rockus/van L 1989 Yang/Gallagh 1989 Primic-Zakelj ⁷ 1989 Primic-Zakelj ⁷ 1981 Rawnihar ¹⁸ 1983 WHO (develop 1984 Clavel ³¹ 1985 Yu/Yuan/Wan 1988 Rockus/van L 1989 Yang/Gallagh 1989 Primic-Zakelj ⁷ 1980 Vessey ^{4,13} 1981 Rawnihar ¹⁸ 1983 WHO (develop WHO (develop WHO (develop <td></td> <td>96/437</td> <td>101/342</td> <td>-9.7</td> <td>26.6 -</td> <td>11</td> <td>0 69±0 162</td>		96/437	101/342	-9.7	26.6 -	11	0 69±0 162
1987 AmerCancSo 1988 Netherlands C Other ^{5,1114,10} Other ^{5,1114,10} All prospective studies CASE-CONTROL STUI 1976 Brinton ³⁴ 1980 Bernstein/Pike 1981 Hissop ⁸ 1983 Lexert ³⁶ 1983 LKNational ²⁵ 1984 Long Island ³³ 1985 Yu/Yuan/Wan 1986 Paul/Skegg ⁸⁸ 1987 Daling ⁵⁰ 1988 AStateStudy ⁴² 1989 Yang/Gallagh 1989 Primic-Zakelj ¹ 1980 Vessey ^{4,13} 1981 Ravinhar ¹⁰ 1983 WHO (develog 04ther/2:10.12:172 MHC (develog 1980 Vessey ^{4,13} 1981 Ravinhar ¹⁰ 1983 WHO (develog WHO (develog ¹¹ 1987 1987 LaVecchla ⁴⁵ 1987 LaVecchla ⁴⁵		1105/4243	1645/6703	35-6	431-0		1 09±0 050
988 Netherlands C Other ^{5,11,14,10} All prospective studies CASE-CONTROL STUD 976 Brinton ³⁴ 980 Bernstein/Pike 981 Hisiop ³ 983 Bernstein/Pike 984 CASH ³⁴ 983 Bernstein/Pike 984 Main/Siskind ²⁷ 985 Yu/Yuan/Wan 986 Paul/Skegg ²⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴⁷ 989 Yang/Gallagh 989 Primic-Zakel[¹ 981 Ravinkar ¹³ 985 VUSH ³³ Other ^{2,10,12,172} All case-control studies 980 Vessey ^{5,13} 981 Ravinhar ¹⁸ 983 <who (develop<="" td=""> WHO (develop 986 Clave³¹ 987 LaVesch⁴⁵</who>		741/2905	594/2418	11-5	209.2		1 06±0 071
Other ^{3,11,14,16} All prospective studies CASE-CONTROL STUI 976 Brinton ⁷⁴ 980 Bernstein/Pike 981 Histop ⁸ 983 Darixstein/Pike 984 CASH ³⁴ 983 Bain/Siskind ²⁵ 984 Cash ³⁴ 985 Yu/Yuan/Wan 985 Paul/Skeg2 ³⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴³ 989 Paul/Skeg2 ³⁶ 989 Yang/Galagh 989 Paul/Skeg2 ³⁶ 988 AStateStudy ⁴³ 989 Paul/Skeg2 ³⁶ 989 Yang/Galagh 989 Paul/Skeg1 ⁴³ 980 VastateStudy ⁴³ 981 Ravnihar ¹⁸ 983 WHO (develop 984 Clavel ³¹ 985 Yu/Yuan/Yuan 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop		264/1091	907/3671	1.5	93-4	1	1 02±0 104
All prospective studies CASE-CONTROL STUI 976 Brinton ⁷⁴ 980 Bernstein/Pike 981 CASH ³⁴ 983 Bain/Siskind ²⁵ 983 Bain/Siskind ²⁵ 983 Bain/Siskind ²⁵ 984 Meirik/Lund ⁹ 984 Long Island ³⁵ 985 Yu/Yuan/Wan 985 Paul/Skegg ³⁶ 986 AStateStudy ⁵¹ 988 AStateStudy ⁵¹ 988 Primic-Zakelj ⁶ 989 Primic-Zakelj ⁶ 981 Ravinlar ¹⁸ 983 WHO (develop 984 Clavel ³¹ 985 Paul/Sel ³¹ 986 Paul/Skegg ³⁶ 987 Daling ⁵⁰ 988 Rookus/van L 989 Primic-Zakelj ⁶ 991 WiSH ³³ Other ^{210,12,17,17} All case-control studie 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983	Netherlands Cohort ⁴⁰	105/40 B	348/1248	29	46 1	1	1 06±0 152
ASE-CONTROL STUI 976 Brinton ³⁴ 980 Bernstein/Pike 981 Hislop ^a 983 UKNational ²⁵ 983 Bain/Siskind ²⁷ 983 Bain/Siskind ²⁷ 983 Bain/Siskind ²⁷ 983 Ewart2 ³⁶ 984 Long Island ³³ 984 Clarke ³⁹ 985 Yu/Yuan/Wan 985 Paul/Skegg ²⁶ 987 Daling ⁵⁰ 988 Rookus/van L 989 Yang/Gallagh 981 Rookus/van L 983 WISH ³³ Other ² 10.12.177 Nil case-control studie 980 Vessey ^{4.13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 987 LaVecchla ⁴⁵	Other ^{5,11,14,18}	138/431	436/1576	25	25-4	1	1.10±0.208
976 Brinton ³⁴ 980 Bernstein/Pilk 981 Hisiop ⁸ 981 CASH ³⁴ 983 UKNational ²⁵ 983 Burstein/Pilk 983 UKNational ²⁵ 983 Ewertz ³⁶ 984 Long Island ³⁵ 984 Clarke ³⁹ 984 Clarke ³⁹ 985 Yu/Yuan/Wan 987 Daling ⁵⁰ 988 4StateStudy ⁴² 989 Yang/Gallagh 989 Primic-Zakel[⁶ 991 WISH ³³ Other ^{2,10,12,172} NII case-control atudite 2ASE-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁶ 983 WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵	spective studies	2647/10243	4159/16534	573	887 3	Þ	1 07±0 035
980 Bernstein/Pike 981 Hisiop ^a 981 CASH ³⁴ 983 UKNational ²⁵ 983 Buln/Siskind ²⁷ 983 Buln/Siskind ²⁷ 984 Meink/Lund ⁹ 984 Long Island ³⁵ 984 Long Island ³⁵ 984 Clarke ³⁹ 985 Yu/Yuan/Wan 987 Daling ⁵⁰ 988 4StateStudy ⁴⁷ 989 Yang/Gallagh 989 Primic-Zakel[⁶ 991 WISH ³³ Other ^{2,10,12,172} All case-control studie 980 Vessey ^{1,13} 981 Ravnihar ¹⁶ 983 WHO (develop 984 Clavel ³¹ 987 LaVecchla ⁴⁵ 987 LaVecchla ⁴⁵	CONTROL STUDIES, WIT	TH POPULATION CO	ONTROLS				
981 Hislop ⁸ 981 CASH ³⁴ 983 UKNational ⁴⁵ 983 Baln/Siskind ²¹ 983 Ewertz ³⁵ 984 Meirk/Lund ⁹ 984 Clarke ³⁸ 984 Clarke ³⁹ 984 Clarke ³⁹ 985 Yu/Yuan/Wan 986 AStateStudy ⁴³ 987 Daling ⁵⁰ 988 Rookus/van L 989 Primic-Zakelj ⁴ 981 Rookus/van L 980 VuSH ⁵³ Other ² :10:12:17; All case-control studie 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 986 Clavel ³¹ 1987 LaVecchla ⁴⁵		714/781	2503/2764	140	1937	-	1 07±0 075
981 CASH ³⁴ 983 UKNational ²⁵ 983 Baln/Slskind ²⁵ 983 Ewertz ³⁶ 984 Meirik/Lund ⁹ 984 Long Island ³⁵ 985 YuYuan/Wan 985 Paul/Skegg ³⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴⁵ 989 Yang/Gallagh 989 Yang/Gallagh 989 Yang/Gallagh 989 Yang/Gallagh 981 Rookus/van L 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecch ³¹	Bernstein/Pike ^{3,27}	373/369	66/70	03	213	T	1 01±0 218
983 UKNational ²⁵ 983 Bain/Siskind ²² 983 Ewertz ³⁵ 984 Long Island ³⁵ 984 Long Island ³⁵ 984 Long Island ³⁵ 985 YulYuan/Wan 985 YulYuan/Wan 985 YulYuan/Wan 985 Paul/Skegg ²⁸ 987 Daling ⁵⁰ 988 AStateStudy ⁴² 989 Primic-Zakelj ⁶ 991 WISH ³³ Other ^{2,10,12,172} All case-control studie 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 987 LaVecchla ⁴⁵	Hisiop ^a	370/414	579/535	-5-0	51.5	1	0 91±0 133
983 Bain/Siskind ²¹ 983 Ewertz ³⁵ 984 Meirk/Lund ⁹ 984 Long Island ³³ 984 Clarke ³⁸ 985 Yu/Yuan/War 986 AttateStudy ⁴² 987 Daling ⁵⁰ 988 AttateStudy ⁴² 989 Primic-Zakelj ⁴ 989 Primic-Zakelj ⁴ 989 Polkars 989 Polkars 989 Paul/Statelj ⁴³ 989 Primic-Zakelj ⁴ 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 987 LaVecchla ⁴⁵	CASH ³⁴	2815/2872	1879/1784	-27.9	394 7	- E	0 93±0 049
983 Ewertz ³⁶ 984 Meirik/Lund ⁹ 984 Long Island ³⁵ 984 Clarke ³⁹ 985 Yu/Yuan/Wan 985 Paul/Skegg ²⁶ 988 4StateStudy ⁴⁷ 988 AStateStudy ⁴⁷ 988 Primic-Zakelj ⁶ 991 WISH ³³ Other ^{2,10,12,17,7} All case-control studie population controls CASE-CONTROL STUI 981 Ravnihar ¹⁶ 983 WHO (develop WHO (develop 984 Clavel ³¹ 987 LaVecchi ⁴⁵	UKNational ²⁵	684/673	71/82	5.9	31-2	- 3	1 20±0 197
984 Meirik/Lund ⁹ 984 Meirik/Lund ⁹ 984 Clarke ³⁸ 985 Yu/Yuan/Wan 985 Yu/Yuan/Wan 985 Yu/Yuan/Wan 985 Paul/Skeg2 ³⁶ 987 Daling ⁵⁰ 988 AStateStudy ⁴⁷ 988 Rookus/van L 989 Primic-Zakelj ⁴ 991 WISH ³³ Other ^{2,10,12,17,17} 911 WISH ³³ Other ^{2,10,12,17,17} 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop WHO (develop 886 987 LaVechla ⁴⁵ 987 LaVechla ¹⁴	Bain/Siskind ²³	197/424	343/671	-3-9	31-6	1	0.88±0.167
984 Long Island ³³ 984 Clarke ³⁹ 985 Yu/Yuan/Wan 985 Paul/Skegg ²⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴³ 988 Rockus/van L 989 Yang/Gallagh 989 Yang/Callagh 989 Primic-Zakelf 991 WISH ³³ Other ^{2,10,12,17,2} Nil case-control studie 930 Vessey ^{4,13} 940 Vessey ^{4,13} 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop ³¹) 987 LaVecd ¹⁴⁴⁵ 987 LaVecd ¹⁴⁴⁵	Ewertz ³⁵	479/458	1066/941	-40	BD-B		0.95±0 109
984 Long Island ³³ 984 Clarke ³⁹ 985 Yu/Yuan/Wan 985 Paul/Skegg ²⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴³ 988 Rookus/van L 989 Yang/Gallagh 989 Yang/Callagh 989 Yang/Callagh 989 Yang/Callagh 989 Yang/Callagh 980 Yeng/Callagh 991 WISH ³³ Other ^{2,10,12,17,17} 981 Rownitation controls 285E-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 386 987 LaVectal ⁴⁵ 987 LaVectal ⁴⁵	Meirik/Lund ⁹	289/338	133/189	87	42-0	1	1-23±0 171
984 Clarke ³⁸ 985 Yu/Yuan/Wan 985 Paul/Skegg ²⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴² 988 Rookus/van L 989 Yang/Gallagh 989 Yang/Callagh 989 Yang/Callagh 989 Primic-Zakelj 991 WISH ³³ Other ^{2,10,12,17,2} 980 Vessey ^{4,13} 980 Vessey ^{4,13} 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop WHO (develop ³⁶ 987 LaVecchla ⁴⁵ 987 LaVecchla ⁴⁵		266/230	914/950	13.8	57.2		1 27±0 149
985 Yu/Yuan/Wan 985 Paul/Skagg ²⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴⁵ 988 Rookus/van L 989 Yang/Gallagh 989 Yang/Gallagh 989 Yintric-Zakeli ⁴ 991 WiSH ³³ Other ^{2,10,12,17,17,17,17,10} Vil case-control studie population controls ASE-CONTROL STUII 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 987 LaVecchla ⁴⁵¹ 987 LaVecchla ⁵¹		257/543	350/669	-40	478	1	0.92±0.139
985 Paul/Skagg ²⁶ 987 Daling ⁵⁰ 988 4StateStudy ⁴² 988 Rookus/van L 989 Yang/Gallagh 989 Primic-Zakeli ⁴ 981 Rokus/van L 989 Primic-Zakeli ⁴ 991 WISH ³³ Other ^{2,10,12,172} Nil case-control studie population controls cASE-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 987 LaVecchla ⁴⁵		184/180	650/654	67	44.0	i	1.16±0.163
987 Daling ⁵⁰ 988 4StateStudy ⁴² 988 Rookus/van L 989 Yang/Gallagh 989 Primic-Zakeli ⁴ 981 WiSH ³³ Other ^{2,10,12,172} Vil case-control studie population controls cASE-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 987 LaVecchla ⁴⁵		674/1521	217/343	45	69.2	1	1 07±0 124
988 4StateStudy ⁴³ 988 Rookus/van L 989 Yang/Gallagh 989 Primic-Zakelj ⁶ 991 WISH ³³ Other ^{2,10,12,173} Vil case-control studie population controls cAse-control studie 980 Vessey ^{5,13} 981 Ravnihar ¹⁶ 983 WHO (develop WHO (develop 987 LaVeccla ⁴⁵ 987 LaVeccla ⁴⁵		685/875	62/86	-0.0	26.5	F	1 00±0 194
988 Rookus/van L 989 Yang/Gallagh 989 Primic-Zakeli ⁶ 991 WISH ³³ Other ^{2,10,12,17,2} NII case-control studie population controls XASE-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁹ 983 WHO(develop WHO (develop 886 Clavel ³¹ 987 LaVecchla ⁴⁵ 987 Eranceschi ⁵¹				8.9	416.6	Li -	1 02±0 050
989 Yang/Gallagh 989 Primic-Zakeli ⁰ 991 WISH ³³ Other ^{2,10,12,172} All case-control studie population controls 285E-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁹ 983 WHO (develop WHO (develop WHO (develop 886 Clavel ³¹ 987 LaVecchla ⁴⁵ 1987 Franceschi ⁵¹		2427/3726	4443/5793			1	1 07±0 163
989 Primic-Zakelj ⁶ 991 WISH ³³ Other ^{2,10,12,17,2} All case-control studie population controls 2ASE-CONTROL STUU 980 Vessey ^{4,13} 981 Ravnihar ¹⁹ 983 WHO (develop WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 987 Eranceschi ⁵¹	Rookus/van Leeuven		137/136	2.5	40-0	1	
991 WISH ⁵³ Other ^{2,10,12,17,2} All case-control studie population controls CASE-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO(develop WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 1987 Eavecchla ⁴⁵		407/441	609/584	-15-3	55 1	1	0.76±0118
Other ^{2,10,12,17,2} All case-control studie population controls CASE-CONTROL STUD 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop WHO (develop 986 Clavel ³¹ 1987 LaVechla ⁴⁵ 1987 Enceschi ⁵¹	···· •	296/297	323/322	30	58-1	1	1-05±0-135
All case-control studie population controls CASE-CONTROL STUI 980 Vessey ^{4.13} 981 Ravnihar ¹⁹ 983 WHO (develop WHO (develop WHO (develop 986 Clavel ³¹ 987 LaVeccla ⁴⁵	WISH ³³	1532/1597	334/412	20.5	119.8	1	1.19±0-100
population controla CASE-CONTROL STUR 980 Vessey ^{4,13} 981 Ravnihar ¹⁹ 983 WHO (develop WHO (develop WHO (develop 886 Clavel ³¹ 987 LaVecchla ⁴⁵ 992 Franceschi ⁶¹	Other ^{2,10,12,17,21,39,62}	1563/2029	1417/2141	16-3	168-5		1 10±0 081
ASE-CONTROL STUI 980 Vessey ^{4,13} 981 Ravnihar ¹⁸ 983 WHO (develop WHO (develop 886 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 982 Franceschi ³¹		14993/18550	16096/19126	44.8	1949 6	-	1 02±0 023
981 Ravnihar ¹⁹ 983 WHO(develop WHO (develop 986 Clavel ³¹ 1987 LaVecchia ⁴⁵	-CONTROL STUDIES, WI	TH HOSPITAL CONT	ROLS				
983 WHO(develop WHO (develop 986 Clavel ³¹ 987 LaVecchla ⁴⁵ 1992 Franceschi ⁵¹	Vessey ^{4,13}	963/972	1420/1419	85	193-4	-	1.04±0.074
983 WHO(develop WHO (develop 986 Clavel ³¹ 1987 LaVecchla ⁴⁵	Ravnihar ¹⁸	161/460	370/1479	26.6	59 2	1	1.57±0.163
WHO (develo 1986 Clavel ³¹ 1987 LaVecchia ⁴⁵ 1992 Franceschi ³¹	WHO(developing) ³⁰	525/5117	1180/9936	27.6	177-1	-	1-17±0 081
986 Clavel ³¹ 1987 LaVecchia ⁴⁵ 1992 Franceschi ⁵¹	WHO (developed)30	667/1933	922/2116	10.9	157-6	-	1-07±0-082
987 LaVecchia ⁴⁵ 1992 Franceschi ⁸¹		247/424	248/472	8.6	44-1	T	1 21±0 166
992 Franceschi ⁸¹		366/238	2897/2490	30.2	94-1	i	- 1 38±0 121
	Franceschi ⁸¹	382/314	2187/2274	25-3	104.7		1.27±0.111
Other ^{6 7,20,29,3}	Other ^{6,7,20,29,32,36,43,44}	616/1378	1879/3543	10 1	102 5		1·10±0·104
Ali case-control atudi hospital controls	se-control studies, with bital controls	3927/10836	11103/23729	147-8	932-7	0	1 17±0 035
ALL STUDIES	STUDIES	21567/39629	31358/59389	249-8	3769 6		1.07±0.017

Test for heterogeneity between study designs: X² (2 df)=11.6; p=0.003 Test for heterogeneity between studies: X² (33 df)=51.6; p=0.02

Figure 1: Relative risk of breast cancer in ever-users compared with never-users of combined oral contraceptives

Separate results are given for individual studies. Each relative risk and its 99% CI is plotted as a black square and a line. The area of the square is proportional to the amount of statistical information (ie, to the inverse of the variance of the logarithm of the relative risk). Diamonds indicate 99% CIs for totals. The solid vertical line represents a relative risk of 1.0 and the broken vertical line indicates the overall relative risk estimate for all studies combined.

*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

throughout the world have used them.¹ The most widely used type of hormonal contraceptive has been the combined oral contraceptive, which contains an oestrogen and progestagen and is prepared from various compounds in various doses and combinations. Other hormonal contraceptives contain progestagen only, given orally or by injection. Many epidemiological studies have investigated whether hormonal contraceptives might affect breast cancer risk,²⁻⁶⁵ and the Collaborative Group on Hormonal Factors in Breast Cancer was set up in 1992 to bring together, reanalyse, and publish the worldwide data. The main results are summarised here. Additional results, together with full descriptions of the methods, the studies and the women included, are being published elsewhere.⁶⁶

Methods

Identification of studies and collection of data

Epidemiological studies that included at least 100 women with breast cancer and that obtained information on the use of hormonal contraceptives and on reproductive history were eligible for inclusion. Studies were identified from review articles, from computer-aided literature searches, and from discussions with colleagues. Special efforts were made to identify all studies that included relevant information, irrespective of whether results on hormonal contraceptives had been published. The principal investigators of all studies identified were invited to collaborate. Subsequently a list of studies and references was sent to collaborators and they were asked if they knew of further studies that were not listed; the principal investigators of those studies

a: Relative risk of breast cancer by total duration of use of combined oral contraceptives Total duration

ofuse	RR*±SD	Cases/Controls	RR* & 99% CI
Never-user	1-00±0-013	28200/55220	6
<1 yr	1-07±0-023	4403/8954	
1-4 yr	1-05±0-018	7036/13305	
5-9 yr	1.09±0.022	4999/8665	
10-14 yr	1.16±0.033	2394/3845	
≥15 уг	1.08±0.063	625/998	-0-
		0.0	0.5 1.0 1.5 2.0

Test for heterogeneity within users: X2 (4 df)=8-0; NS Test for trend within users: X² (1 df)=3.9; p=0.05

004400

c: Relative risk of breast cancer by time since first use of combined oral contraceptives Time since first

RR'±SD	Cases/Controls	HR & SS% CI	
1 00±0-013	28200/55220		
1-09±0-058	760/2337	-	
1.19±0-036	2352/4585		
1-11±0-024	4789/8269		
1 05±0-023	5796/9186		
1.03±0.029	4235/7143		
	0.0	1.5 1.0 1.5	2.0
	1 00±0-013 1-09±0-058 1-19±0-036 1-11±0-024 1 05±0-023	1 00±0 013 28200/55220 1 09±0 058 760/2337 1 19±0 036 2352/4585 1 11±0 024 4789/8269 1 05±0 023 5796/9186 1 03±0 029 4235/7143	1 00±0.013 26200/55220 1.09±0.058 760/2337 1.19±0.036 2352/4585 1.11±0.024 4789/8269 1.05±0.023 5796/9186 1.03±0.029 4235/7143

Cases/Controls BP* & 00% C

Test for trend within users: X² (1 df)=9.6; p=0.002

b: Relative risk of breast cancer by age at first use of combined oral contraceptives

Age at first use RB*±SD Cases/Controls RR* & 99% CI Never-use 28200/55220 1-00±0-014 <20 yr 2719/4205 1-2210-044 20-24 vr 5334/9111 1 04±0 025 25-29 yı 3888/7205 1 06±0 025 30-34 vi 2932/5412 1.06±0.030 ≥35 yr 3059/5590 1.11±0 032 0.0 0.5 1.0 1.5 2.0 Test for heterogeneity within users: X# (4 df)=13.4; p=0-01

Test for trend within users: X² (1 df)=0.2: NS

d: Relative risk of breast cancer by time since last use of combined oral contraceptives



Test for heterogeneity within users: X[#] (4 df)=41.5; p<0.00001 Test for trend within users: X² (1 df)=31.7; p<0.00001

Figure 2: Relative risk of breast cancer for various indices of timing of use of combined oral contraceptives Each analysis includes aggregated data from all studies. Variance calculations are based on floating absolute risks⁷ which ascribe an appropriate variance not only to the relative risk for each category of use but also to the relative risk of 1.0 for never-users. The area of each square is proportional to the amount of statistical information and CIs are drawn as white lines when they are so narrow that they lie entirely within the width of the square. *Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased

were also invited to collaborate. Few additional studies came to light from such enquiries, and in view of the wide consultation it seems unlikely that any substantial ones have been missed. Of the eligible studies identified,2-65 original data were available for this analysis from 54, of which 52 have been published.2-53 Original data could not be retrieved for 11 studies⁵⁴⁻⁶⁴ and one research group declined to take part in the collaboration.65

Data for individual women were sought on sociodemographic factors, use of hormonal contraceptives and hormone replacement therapy, family history of breast cancer, height, weight, age at menarche, reproductive history, menopausal status, age at menopause, gynaecological surgery, and alcohol consumption. Information on tumour spread was sought for women with breast cancer. Similar data were sought from prospective studies and from case-control studies. Prospective studies were included by means of a nested case-control design, with four randomly matched controls for each woman with breast cancer.66 The availability of data on individual women permitted a wide range of consistency checks to be made. Apparent inconsistencies, implausibilities, or omissions were clarified with collaborators and, where appropriate, rectified. Summary tables and listing of the variables used in these analyses were supplied to the investigators for checking.

Information on hormonal contraceptives, reproductive factors, and tumour stage had been collected in fairly comparable ways in most studies, or could be derived simply, so that use of similar definitions across all studies was generally straightforward. The only material difference between the studies was in the recording of durations of use of less than a year, so analyses were repeated with ever-users defined as women with durations of use of more than a year, but this approach made little difference to the main

findings.66 Information on the type and dose of oestrogen and of progestagen in the hormonal contraceptive that each woman had used first, had used last, and had used for the longest period of time was available for 27 studies3,4,9,10,12,13,15,18,24-26,28,30,33,34,37,38,40,41,48-53 (and the two unpublished studies). Preparations were grouped into three broad categories of dose-low, medium, and high (containing <50 µg, 50 µg, >50 µg, oestrogen, respectively; this classification scheme is strongly correlated with progestagen dose as well as with oestrogen dose.⁵⁶ Only invasive breast cancers were included in these analyses, and information that permitted their classification into cancers that were localised to the breast and those that had spread to axillary lymph nodes or to distant sites was available for 24 studies (and the two unpublished studies), 2,4,8,16,20-23,25,30-35,37.43,48-50,52,53

Statistical analysis

Data from different studies are combined by the Mantel-Haenszel stratification technique.67 To ensure that women in one study are compared directly only with similar women in the same study, all analyses are stratified by study, as well as by other factors, described below. The stratum-specific quantities that are calculated are the standard observed minus expected (O-E)numbers of women with breast cancer, together with their variances, var(O-E), and covariances.^{66,69} Use of these simple stratified O-E values in preference to more complex mathematical models sacrifices some statistical power but has the advantage of avoiding assumptions about the precise forms of any relations in the data.

The stratified O-E values, together with their variances and covariances, yield both statistical tests (p values) and statistical descriptions (odds ratios, subsequently referred to as relative



Figure 3: Relative risk of breast cancer for various indices of the timing of combined oral contraceptive use within categories of time since last use

Format as in figure 2. Of 15 tests for heterogeneity, one within each time since last use category, two are statistically significant: age at first use in current users (χ^2 =12·7, df \approx 3, p=0·005) and age at first use in women whose last use was 1–4 years ago (χ^2 =12·6, df \approx 3, p=0·006). *Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

risks). Relative risk estimates are obtained from O-E values by the one-step method that has been widely used in overviews of clinical trials.⁷⁰ Although this method may not be appropriate for estimating relative risks of two-fold or greater, it should satisfactorily estimate less extreme relative risks; when the main analyses were repeated by maximum likelihood methods, the results were virtually identical.⁸⁶ In analyses involving comparisons of more than two groups, the confidence intervals associated with these relative risks are estimated by treating the relative risks as floating absolute risks.⁷¹ The use of floating absolute risks does not alter the relative risk estimates, but it reduces the variances attributed to them and reduces unwanted covariances between the groups. This approach also attributes an appropriate variance estimate to the group arbitrarily chosen as the baseline group—ie, the group with relative risk set to one.

All analyses are routinely stratified by study, by centre within study for multicentre studies, and by fine divisions of age (16, 17, 18...63, 64, 65-69, 70-74, 75-79, 80-84, 85-89). Of the remaining variables that might confound the relation between breast cancer risk and oral contraceptive use, reproductive history and age at which a woman ceases to be at risk of conception are particularly important; other factors that were considered, such as family history, ethnic group, or weight, do not confound the main relations." The basic stratification procedure, therefore, also included one variable representing reproductive history (nulliparous women formed a separate stratum, and parous women were cross-classified according to three divisions of age at first birth: <20, 20–29, \geq 30; and two divisions of parity; 1–2, \geq 3) and a second variable representing the age at which a woman ceased to be at risk of conception (taken to be the youngest age at which hysterectomy, tubal ligation, bilateral oophorectomy, or natural menopause occurred, and categorised as: still at risk of conception, <35, 35-39, 40-44, 45-49, ≥50). Women with unknown values for a particular stratification variable were allocated to a separate stratum.

Presentation of results

1716

For many analyses, results are presented in the form of plots of adjusted relative risks. Because of the large number of estimates involved, 99% CI are used in most instances, with 95% CI used

only for summarising the main findings. Each relative risk is plotted as a black square, the area of which is inversely proportional to the variance of the logarithm of the estimate, and is hence an indication of the amount of statistical information available for that particular estimate. The corresponding 99% CI

Age at diagnosis of breast cancer and timing of use of combined oval contraceptives	RR*±SD	Cases/Controls	Age-specific relative risk of breast cancer RR* & 99% Ci
AGE <30 AT DIAGNOSIS			
Never-user	1-00±0-118	290/2995	
<5 years since last use; <20 at first use <5 years since last use; ≥20 at first use 5-9 years since last use ≥10 years since last use	1 95±0 134 1 14±0-098 1-16±0-143 Insufficient dala	348/916 254/1075 134/412 18/48	+
AGE 30-34 AT DIAGNOSIS Never-user	1-00±0-067	690/2093	+
<5 years since last use: <20 at first use <5 years since last use 5-9 years since last use ≥10 years since last use	1 54±0-101 1 13±0 058 1 08±0 060 0 96±0 065	437/498 745/1454 629/1163 293/586	-
AGE 35-39 AT DIAGNOSIS			
Never-user	1 00±0-047	1459/3322	-til-
<5 years since last use; <20 al first use <5 years since last use; >20 at first use 5-9 years since last use ≥10 years since last use	1 27±0-116 1 16±0-055 1 00±0-049 1 03±0-044	257/278 965/1660 899/1582 1286/2081	*
AGE 40-44 AT DIAGNOSIS			
Never-user	1 00±0-035	2958/5392	1
<5 years since last use; <20 at first use <5 years since last use; ≥20 al first use 5-9 years since last use ≥10 years since last use	Insufficient date 1-22±0-057 1-13±0-051 1-01±0-034	45/43 942/1443 1024/1528 2222/3258	-
AGE ≥45 AT DIAGNOSIS Never-user	1 00±0-017	22803/41418	
<5 years since lest use; <20 at first use <5 years since last use; >20 at first use	Insufficient data 1-11±0-053	1/4 1029/1577	-
5-9 years since last use	1 15±0.043	1405/2340	-
≥1D years since last use	0 99±0-021	4427/8468	2

Test for brend with age at diagnosis in women with last use 45 years ago, agent fifts use 420; x² (1 40)–62; p=0.02 last use 45 years ago, agent first use 420; x³ (1 40)–60; NS last use 59 years ago: x² (1 40)–61; NS last use 59 years ago: x² (1 40)–61; NS

Figure 4: Age-specific relative risk of breast cancer by time since last use of combined oral contraceptives

Format as in figure 2, within categories of age at diagnosis. *Relative risk (given with 99% Cl) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a worman was when her first child was born and the age she was when her risk of conception ceased. is drawn as a line; CIs that extend beyond the scale of the plot are indicated by an arrow.

There are two main types of plot. The first type involves a twoway comparison such as ever-use versus never-use, and gives the results separately for all the studies with substantial amounts of statistical information, the remaining studies being included in the relevant other category. In these plots the overall estimate is calculated from the sum of the study-specific values for O-E and var(O-E). The second type of plot describes the results of categorical analyses involving more than two groups, with variances estimated via the method of floating absolute risks, representing the aggregated results from all relevant studies. Heterogeneity of relative risks and, where appropriate, linear trends are assessed by χ^2 tests.

Results

The 54 studies contributing to these analyses were conducted in 25 countries, mostly in Europe and North America, but Asia, Australasia, Africa, and Latin America were also represented. Together the studies included 53 297 women with invasive breast cancer (cases) and 100 239 women without breast cancer (controls). The median age at diagnosis of breast cancer was 49 years, and the median year of diagnosis was 1984. At the time of diagnosis, 9% of women with breast cancer were younger than 35, 25% were 35–44, 33% were 45–54, and 33% were 55 and older. Further details of the design of each study and of the women included are given elsewhere.⁶⁶ The analyses here excluded 22 cases and 125 controls who were aged 15 or younger or 90 or older, and 350 cases and 1096 controls with unknown use of oral contraceptives.

Ever-use of combined oral contraceptives

Overall, 21 567 (41%) of the women with breast cancer and 39 629 (40%) of the women without breast cancer had ever used combined oral contraceptives. Figure 1 shows for individual studies the numbers of ever-users and never-users and the corresponding relative risk estimates associated with ever-use. The studies are arranged according to study design-prospective studies, casecontrol studies with population controls, and case-control studies with hospital controls. Within the groups the studies are listed in chronological order, according to the median year of diagnosis of breast cancer. The results for studies in which the information content, var(O-E), was less than 20.0 are included in the category "other" for the relevant study design. Overall the relative risk of breast cancer in women who had ever used oral contraceptives compared with women who had never used them was slightly above 1.0, and the excess was statistically significant (relative risk 1.07 [SD 0.02], 2p=0.00005). There was some evidence of heterogeneity in the results both between the individual studies and between the three types of study design. Ever-use is, however, a crude measure of exposure and represents different patterns of oral contraceptive use in different studies.66 Breast cancer risk is therefore considered in relation to various different features of oral contraceptive use that have been thought to be of possible importance.

Timing of exposure

Breast cancer risk is described in relation to four indices of the timing of exposure to combined oral contraceptives total duration of use, age at first use, time since first use, and time since last use. These four indices are highly correlated,⁶⁶ so if breast cancer risk is directly related to

Use of combined oral contraceptives in relation			Relative risk of breast cancer		
to childbearing	RR*±SD	Cases/Controls	RR* & 99%CI		
Never-user	1-00±0-018	28200/55220			
NULLIPAROUS WOMEN					
Current user	1 30±0 098	516/883			
Last use 1–4 yr ago	1-13±0-092	418/639			
5–9 yr ago	1 02±0 082	472/610			
10-14 yr ago	0 99±0 086	411/477	-		
≥15 yr ago	1.02±0.099	338/432	-		
PAROUS WOMEN WHO BEGAN I OF THEIR FIRST CHILD	USE BEFORE THE	BIRTH			
Current user	1 33±0 081	605/862			
Last use 1-4 yr ago	1 36±0 076	744/1046	-8-		
5–9 yr ago	1-10±0 054	1072/1582	-		
10-14 yr ago	1 04±0 051	1159/1595	*		
≥15 yr ago	1 07±0 055	1106/1509	-		
PAROUS WOMEN WHO BEGAN	USE AFTER THE I	зіятн			
Current user	1.21±0.054	1142/2317	-		
Last use 1-4 yr ago	1.11±0-045	1448/2827	-		
5–9 yr ago	1-11±0-036	2473/4625			
10-14 yr ago	0.97±0.032	2514/5040			
≥15 yr ago	1.00±0.034	2611/5140	#		
		0.0 0.5	10 15 24		

Figure 5: Relative risk of breast cancer by time since last use of combined oral contraceptives and in relation to childbearing history

Format as in figure 2.

*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

any one, it is likely to be indirectly related to the others. To find out which of the four relations is most direct, the one most strongly related to risk was identified, and then, holding that one factor constant, the other three relations were re-examined. Subsequently breast cancer risk was investigated in relation to other indices of exposure, and the consistency of the main findings was explored in women of different ages and with varying background risks of developing breast cancer.

Total duration of use (figure 2a)—A quarter of everusers were reported to have used oral contraceptives for less than a year and the median total duration of use was 3 years. The relative risk was slightly above 1.0 for each of the five broad categories of use. There was no significant heterogeneity of relative risk of breast cancer between the categories of duration of use, but there was a weak indication of a trend of increasing risk with increasing duration (p=0.05).

Age at first use (figure 2b)—The age at starting use of combined oral contraceptives ranged from early teens to early 40s, with a median of 26; 14% of women had begun use before age 20 and 17% at age 35 or older.⁶⁶ The relative risk was slightly greater than 1.0 for each of the five age groups and was largest for women who started use as teenagers. There was some heterogeneity in the relative risks between the five categories of age at first use (p=0.01) but no significant trend with increasing age at first use.

with		Relative risk of breast cancer associated with last use of oral contraceptives <\$ years ago versus never use		b: Relative risk of breast cancer associated with last use of oral contraceptives 5-9 years ago versus never use			c: Relative risk of breast cancer associated with last use of oral contraceptives ≥10 years ago versus hever use		
Characteristic	RR'480	Cases/Controls	HR* & 99%CI	RR*±SD	Cases/Controls	RR* & 99% Cl	RR*-SD	Cases/Controls	AB. 98%CI
NOTHER AND/OH SISTER WI	ITH								1
HISTORY OF BREAST CANCE	1 21:0-035	3858/7467		1 07±0 031	3270/6377		1-02+0-025	6988/13809	100
Yes	1-06:0-153	454/279		1 0210 128	468/367		D 88±0 092	1122/1085	
COUNTRY OF RESIDENCE			-			1			1
Developed	1-1860-031	4777/6789	-	1.06±0-028	4036/6354		1.01±0.023	8554/14642	
Developing	1-38310 106	296/2390		1-31±0-121	203/1334		0.89±0.084	264/1825	
ETHNIC OFIGIN		sico lines	-			100			
White	1.16±0.036	3511/5553		1 04±0-033	2974/5023	194	0 90±0 027	6578/11497	50
Eleck.	1-37±0-244	162/274		1 26±0 237	158/229		1-21±0 185	339/463	
Asilan	1.35±0.128	241/1657		1 19±0 140	165/954		1.02±0.109	255/1491	
Other	1-42±0.188	155/701		1 1810 168	135/503		1 10±0 142	225/786	
YEARS OF EDUCATION		and mills			-	10			
<13 yr	1.24±0.045	2639/5301 2201/3520		1 (04±0 (041) 1 (08±0 (042)	2014/4106 2090/5421	E	0 96±0-034	3613/7189 5030/8905	
13 yr	1-1210-046	2201/3520		1-08::0-042	2090/04/21		1.0310.033	2030/8902	10
AGE AT MENARCHE	1.25±0.054	2076/2871	-	1-13±0 048	1825/2651		1.08+0.039	3963/6373	
13	1.2410-069	1329/2225		1 18±0 065	1136/1894		0.99+0-049	2344/4410	
214	1-27±0.062	1494/3442		1 03:00-064	1179/2780		0 95±0-044	2427/5395	
HEIGHT						E.			-
<160kam	1.18±0-079	975/1285		1-17±0-076	862/1183		1 02±0 059	1724/2867	-
160-168cm	1.17±0-047	2382/2907	-	1 03±0 042	1991/2822	-	1 02±0-034	4494/6663	100
2170 cm	1 19±0-089	932/1132		1-13±0 D82	845/1089		0 90±0 063	1641/2484	-
WEIGHT			-			E			1
<60 kg	1 18±0 054	2096/2761		1 07±0 051	1643/2274		1 01±0 044	2958/4410	
60-69 kg	1.19±0.069	1305/1548	-	0-99±0 059	1088/1575	-	1 00±0-048	2553/3947	*
270 kg	1 20±0 098	642/864	-	1-12±0-081	713/1036		0 98±0-055	1986/3293	-
MENOPAUSAL STATUS			-			-			-
Premanopausal	1-22±0-035	4417/7929		1 07±0-035	2987/5175		1 00:50-031	4967/8018	
Postmenopausal	1.08±0-087	433/881		1 05±0 057	003/1830		1 OO±0 038	2814/5741	
ALCOHOL CONSUMPTION					minuter -	-	and the second	A COMPANY OF	-
-50 g per week	1 2310 044	2588/5703 338/1191	-	107±0.039	2121/4354		0.99±0.031	4443/8776	-
≥50 g per week	1-25±0-087	a38/1191		1 QE±0.074	870/1118	-	0.99±0.059	1746/2581	-
								0.0	0.5 1.0 1.5
			5 1.0 1.6 2.0			0.5 1.0 1.5 2.0			
Giobal test for haterogeneit	ly:	x	2 (14 df)=11 0; NS		2	(14 df)=14 5; NS		x	² (14 df)=13 5; NS

Figure 6: Relative risk of breast cancer by time since last use of combined oral contraceptives among women with different characteristics

Format as in figure 2, except that SDs and Cls are based on conventional variance estimates rather than on those for floating absolute risks. None of the 27 tests for heterogeneity across categories of a particular characteristic is statistically significant.

*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

Time since first use (figure 2c)—Most women who had used oral contraceptives had begun use between 10 and 20 years before diagnosis of breast cancer, or pseudodiagnosis in controls (median 16 years). The relative risks were slightly above 1.0 in each 5-year period of time since first use. There was evidence both of heterogeneity of risk between the five categories (p=0.01) and of a trend of decreasing risk with increasing time since first use (p=0.002).

Time since last use (figure 2d)-Current users include women who were taking oral contraceptives at the time of diagnosis (or pseudodiagnosis) or in the preceding 12 months, and about a quarter of ever-users were included in this category. There was evidence of an increased risk of breast cancer being diagnosed in current users (relative risk 1.24 [SD 0.04], 2p<0.00001) and in women who stopped use 1-4 years previously (1.16 [0.04]), 2p=0.00001), with some evidence of an increased risk 5-9 years after stopping $(1.07 \ [0.03], 2p=0.009)$. For women who stopped use 10 or more years ago, the relative risk did not differ significantly from 1.0 (1.01 [0.02], NS). Virtually all the information on use that ceased more than 10 years ago relates to use that ceased between 10 and 20 years ago. There was substantial heterogeneity in the relative risks between the five categories of time since last use (p<0.00001) and a strong trend of decreasing risk with time since last use (p < 0.00001).

Each of the four χ^2 tests for heterogeneity shown in figure 2 is on four degrees of freedom and each of the tests for trend is on one degree of freedom, so the χ^2 values can be compared directly. On the basis of both types of test, of the four factors examined, time since last use (figure 2d) is most strongly related to breast cancer risk (for heterogeneity, χ^2 =41.5, compared with 8.0, 13.4, and

1718

13.4; and for trend, χ^2 =31.7, compared with 3.9, 0.2, and 9.6).

The increased risk associated with current and recent use and the absence of an increase in risk associated with use that ceased 10 or more years ago remained within each of the categories of the other three indices of exposure (figure 3). Furthermore, when the results according to time since last use were examined in detail to find out whether adjustment for other possible confounders, such as family history of breast cancer, age at menarche, or weight, might modify the magnitudes of the relative risks in figure 2d, none was found to do so.⁶⁹

Residual effects of other indices of exposure, given time since last use

The residual effects of the three other main indices of exposure within each time since last use category are shown in figure 3. No residual effects were evident for total duration of use or for time since first use: none of the tests for trend or heterogeneity was significant for either of these factors within each of the five categories of time since last use. Since breast cancer risk is more strongly related to recent than to past use, it is possible that total duration of use might not be relevant for women who used oral contraceptives intermittently, with long breaks inbetween. However, analyses restricted to women whose entire use of oral contraceptives was interrupted by less than 24 months (pregnancies excluded) also showed no significant trend in breast cancer risk with duration of use, even when use was, in this sense, virtually continuous.⁶⁶ Also, when durations of use were calculated, restricted to the time when women were nulliparous, there was no relation between duration of use while nulliparous and breast cancer risk.66

a: Relative risk of breast cancer in women whose last use of combined oral contraceptives was <5 years ago

b: Relative risk of breast cancer in women whose last use of combined oral contraceptives was ≥5 years ago

Study	RR*±SD	Cases/Controls	RR*&99% CI	RR*±SD	Cases/Controls	RR*&99% Cl
PROSPECTIVE STUDIES RCGP ¹⁵					05/050	
RCGP'	1-29±0189	103/369	1	1 19±0 191	95/359	
Oxford/FPA26	0-91±0 210	67/243	1	0 48±0 203	29/194	
Nurses Health ²²	1-20±0 148	111/387	1	1 10±0 053	928/3554	
Canadian NBSS ³⁷	1 17±0 241	44/156	1	1 05±0 074	648/2548	
Amer Canc Soc42	0-46±0 571	2/10	1	1 03±0 111	215/898	
Netherlands Cohort ⁴⁸	0-81±0759	2/9	1	1.10±0.161	96/368	E.
Other ^{6,11,14,19}	0.56±0.449	19/20	Ŧ.	U-69±0-481	19/50 -	
Il prospective studies	1 14±0 091	348/1194	-	1 07±0 038	2030/7971	Ð
ASE-CONTROL STUDIES, WITH P	OPULATION CON	TROLS				
Brinton ²⁴	1 14±0 127	203/235	1	1-07±0-089	440/474	
Bernstein/Pike ^{3, 27}	1 12±0 254	198/149		0.91±0.235	175/220	
Hislop ^a	1 10±0 297	69/72	1	0 82±0-143	288/337	
CASH ³⁴		607/632	AT.	0 90±0 053	1867/1888	
	1 03±0 097				211/269	-
UK National ²⁵	1 43±0 226	473/404	I	0.81±0-191 No data	211/203	
Bair/Siskind ²³ Ewertz ³⁵	No data	170/15/	1		200/205	
	1 0B±0 167	173/154	1	0.86±0.121	280/285	
Meink/Lund [®]	1 72±0 272	119/121	1	1-09±0-182	169/216	
Long Island ³³ Clarke ³⁸	1.07±0.597	15/14	1	1.31±0.158	234/203	
Clarke	1-34±0-351	59/108		0 86±0 145	189/410	
Yu/Yuan/Wang ^{18,40}	1-31±0-276	59/55		1.08±0.183	125/123	
Paul/Skegg ²⁸	1.11±0.220	136/441		1 06±0 128	538/1079	
Daling ⁵⁰	1 66±0 352	172/236		0 83±0 187	512/639	
4 State Study"	0 63±0 373	49/45	-	1 04±0 114	677/752	
Rookus/van Leeuwen ⁴⁸	1.19±0 234	298/261		0 98±0 168	471/515	
Yano/Gallagher ⁴¹	0 59±0 508	32/31		0.73±0.120	356/387	
Primic-Zakeli ⁴⁸	1 36±0 282	74/55		0 94±0 135	214/242	
Primic-Zakelj ⁴⁸ WISH ⁵³	1 23±0 158	285/301		1 17±0 104	1232/1284	
Other ^{2,10,12,17,21,39,52}	0.99±0154	274/474		1 12±0 088	1235/1485	
li case-control, pop. controls	1-18±0 048	3295/3768	0	0.99±0.027	9213/10808	
CASE-CONTROL STUDIES, WITH H	HOSPITAL CONTR	OLS				
Vessey ^{4,13} Ravnihar ¹⁶	1.07±0.101	468/430		1 03±0 092	485/532	
Beyniher ¹⁶	No data			No data		
WHO (developing) ³⁰	1 29±0 126	216/2156		1 07±0 094	303/2886	
WHO (developed)	1 21±0 124	333/957		0 96±0 095	312/915	
Clavel	0 97±0 191	114/212		1 36±0 216	132/212	
La Vecchia ⁴⁵		77/65	1	1.13±0.142	185/124	
La veccria	1 37±0 234		1	1.31±0.125	292/224	
Franceschi ⁵¹ Other ^{8,7,20,29,32,36,83,44}	1.19±0 201	90/87	1	0.77±0.178	107/482	
	1-37±0/269	132/291				-
All case-control, hosp. controls	1 18±0 057	1430/4198	0	1 07±0 045	1816/5375	-
ALL STUDIES	1 16±0 034	5073/9180	•	1 03±0 020	13059/24154	
		0.0 0			8.0	0.5 1.0 1.5 2.0
est for heterogeneity between study			2 df) =0-2; NS			X ² (2 df) =4 0; NS
Fest for heterogeneity between studi	BS:	X ² (31 df) =21.5; NS			X ² (31 df) =45.7; p=0.04

Figure 7: Relative risk of breast cancer in recent and past users of combined oral contraceptives

Format as in figure 1. Where the upper CI is greater than 2.0, this is indicated by an arrow.

*Relative risk (given with 99% CI) relative to never-users. stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

There was, however, significant heterogeneity of risk by age at first use in current users (p=0.005) and in women who stopped use 1-4 years ago (p=0.006), with current and recent users who began use before age 20 having significantly higher relative risks than women who began at older ages (figure 3b). By contrast, among women whose use ceased 5 or more years ago, the relative risks were not materially affected by the age when use began. For women who began use before age 20 and stopped use more than 15 years ago the relative risk fell from 1.14 to 1.01 when ever-users were taken to be women with a duration of use of greater than a year, suggesting that there may be differential recall between cases and controls of brief use at early ages that ceased long ago.⁶⁶

The effects of other indices of the timing of exposure were examined, including age at last use, year of first use, and year of last use of oral contraceptives; however, no other factor appeared to have much effect on breast cancer risk once account had been taken of time since last use and age at first use.⁶⁶

Consistency of effect of time since last use

Although it is of interest to examine how consistent the main findings appear to be, it should be borne in mind that analyses restricted to particular subgroups may by chance alone yield misleadingly irregular patterns.

Age at diagnosis The pattern of an increased relative risk of breast cancer in recent users (ie, women whose last

use was within the previous 5 years), with no increased risk 10 or more years after cessation of use, was found consistently at all ages (figure 4). Furthermore, for recent users who began use after age 20, and for past users who ceased use 5-9 or 10 or more years previously, the relative risks did not vary significantly with age at diagnosis. For women who began use before age 20 the relative risk associated with current or recent use, although consistently higher than for women who began use at older ages, tended to decline with increasing age at diagnosis. Within specific age groups, there was no statistically significant trend with duration of use, once time since last use and age at first use had been taken into account.⁵⁶

Women with different background risks of breast cancer A woman's reproductive history affects both her use of oral contraceptives and her risk of breast cancer.⁶⁰ Although stratification for various features of reproductive history should avoid material confounding due to those variables, it is of interest to examine whether the results relating to oral contraceptive use are consistent for women with different childbearing patterns. Nulliparous women are a special group in that there is no opportunity for the effects of oral contraceptive use to be modified or confounded by childbearing. In nulliparous women the pattern of risk with respect to time since last use is similar to that found for all women (figure 5). Moreover, among parous women the pattern of risk is similar irrespective of whether oral contraceptive use began before or after the

Vol 347 • June 22, 1996

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Tumour spread	RR*±SD	Combined oral contraceptive use Ever/Never	RR* & 99% CI
Localised to the breast	1 00+0 027	6912/5628	+
Spread to lymph nodes only	0.89±0.029	4535/4152	=
Distant metastases	0.70±0.106	243/419	5 1.0 1.5 2.0

Test for heterogeneity by extent of turnour spread: X² (2 df)=13-2; p=0-001

Figure 8: Analyses relating extent of tumour spread among women with breast cancer to ever-use of combined oral contraceptives

Format as in figure 2. The reference group is women whose cancers are localised to the breast. Relative risk estimates represent the probability that women whose cancers have spread beyond the breast are everusers compared with the probability that women whose cancers are localised to the breast are ever-users.

*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity. and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

birth of the first child (figure 5). Similar patterns of risk with respect to time since last use of oral contraceptives were found for women of different parity and for women who had their first child at different ages.⁶⁶ The relations according to time since last use of oral contraceptives were similar for women with and women without a family history of breast cancer, for women from different countries and ethnic groups, for women of different heights and weights, and in premenopausal and postmenopausal women (figure 6). None of the 27 comparisons made in figure 6 was statistically significant. For each time since last use category ($<5, 5-9, \ge 10$) an overall test of heterogeneity was calculated by summing the nine respective individual χ^2 values to give an overall χ^2 statistic on 14 df. The value of each of these statistics was consistent with what would be expected if there were no heterogeneity in the relative risks by any of the characteristics considered. Separate analyses for recent users who began use before and after age 20 identified no additional variation in risk between these subgroups.⁶⁶

Different studies A slightly increased relative risk of breast cancer among recent users of combined oral contraceptives was found consistently between the three types of study design and between studies, although in most individual studies the excess was not statistically significant (figure 7a). For women who stopped use more than 5 years ago there was also no evidence of heterogeneity between the study designs, and only weak heterogeneity between the individual studies (figure 7b).

Tumour spread

The breast cancers diagnosed in women who had used combined oral contraceptives were significantly less advanced clinically than those diagnosed in never-users. Tumours in ever-users were less likely to have spread to axillary lymph nodes (relative risk 0.89 [SD 0.04],

		Combined oral o	Risk of spread compared to		
Study	RR*±SD	Ever spread/localised	Never spread/localised	localised cance RR* & 99% CI	
				1	
PROSPECTIVE STUDIES		385/623	605/915	1	
Nurses Health ²² Canadian NBSS ³⁷	0-84±0-091 0-85±0 136	245/496	206/388		
Canadian NB33	0.0010 100	2401400	200/200		
All prospective studies	0-85±0-075	630/1119	811/1303	4	
ASE-CONTROL STUDIES, W		CONTROLS			
Hislop ⁸	1.15±0.525	36/186	54/235		
CASH ³⁴	0.97±0.072	1236/1545	851/1019		
UK National ²⁵	0.55±0.235	192/405	27/40		
Bain/Siskind ²³	1.68±0.444	95/85	150/162		
Ewertz ³⁶	0-81±0-165	133/279	375/542		
Long Island ³⁸	1 06±0-231	112/140	363/489		
Daling ⁵⁰	0.61±0.249	283/397	30/30		
Rookus/van Leeuwen ⁴⁹	0.97+0.247	343/414	72/61		
Primic-Zakelj ⁴⁸	0.69±0.201	214/71	260/58		
WISH53	1-12+0-157	652/851	133/193	1	
Other ^{2,21,52}	0.82+0.139	400/787	318/342		
All case-control studies, with population controls	0.93±0 049	3696/5160	2633/3171	¢.	
CASE-CONTROL STUDIES, W	TH HOSPITAL C	ONTROLS		1	
Vessey ⁴	0.60±0.164	64/189	146/271		
Plavnihar ¹⁶	0.75±0.220	55/98	148/201		
WHO ^{3D}	0.61±0.302	160/87	331/225		
Clavel ³¹	0.67±0.237	74/162	90/144		
Other20 32 43	0.99±0.381	99/97	412/313		
All case-control studies, with hospital controls	0.68±0.104	452/633	1127/1154		
ALL STUDIES	0-88±0-038	4778/6912	4571/5628	4>	

Test for heterogeneity between study designs: X² (2 df)=5 6; NS Test for heterogeneity between studies: X (17 df)=19 8; NS

Figure 9: Extent of tumour spread among women with breast cancer in ever-users compared with never-users of combined oral contraceptives

Format as in figure 1.

*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

1720



Figure 10: Relative risk of breast cancer by time since last use of combined oral contraceptives according to extent of tumour spread

Format as in figure 2.

*Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where

appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

2p=0.006) or to more distant sites (0.70 [0.11], 2p=0.006) than to be localised to the breast (figure 8). This finding of a relative deficit of tumours that had spread beyond the breast in ever-users did not differ significantly across the studies with information on tumour spread, nor according to study design (figure 9).

Both for women with localised tumours and for women with more extensive disease, the relation with recency of oral contraceptive use was similar to that found for all women, the relative risks declining significantly with time since last use (figure 10: χ^2 for trend, p=0.004, for each). The relative risk of localised disease was significantly increased in recent users and remained slightly increased 5–9 and 10 or more years after cessation of use (figure 10a). By contrast, the relative risk of cancer that had spread beyond the breast was slightly and non-significantly raised in recent users, and, if anything, was reduced 5–9 and 10 or more years after cessation of use (figure 10b). These results suggest that much of the excess risk of breast cancer in recent users is due to an excess of localised tumours. The magnitude of the relative deficit of more extensive disease did not vary significantly with time since last use of oral contraceptives (test for heterogeneity $\chi^2=3\cdot1$, df=2, NS; overall relative risk 0.88 [SD 0.04], 2p=0.002) and the relative deficit was still evident 10 or more years after use (relative risk 0.85 [SD 0.05], 2p=0.001).

Constituents of hormonal contraceptives

Among women for whom information was available about the particular combined oral contraceptive preparations used, there was no significant variation in the relative risks associated with use of specific types of oestrogen or of progestagen, either in recent or in past users.⁶⁶ When the preparations were grouped into three broad categories according to hormone dose there was, if anything, a decrease in the risk of breast cancer with increasing dose



Figure 11: **Relative risk of breast cancer by time since last use and hormonal dose in combined oral contraceptive last used** Format as in figure 2. Results are given separately for all cancers and for cancers that were localised to the breast and that had spread beyond the breast. Not all studies with information about hormonal dose also provided information about tumour spread. *Relative risk (given with 99% CI) relative to never-users, stratified by study, age at diagnosis, parity, and, where appropriate, the age a woman was when her first child was born and the age she was when her risk of conception ceased.

1721

among women who had stopped use 10 or more years before, largely due to a reduction in breast cancer risk among those who had used the highest-dose preparations (figure 11a). There were no significant trends with duration of use among women who had used low-dose, medium-dose, or high-dose preparations.⁶⁶

The pattern of risk in relation to hormone dose was also examined according to the extent of tumour spread. For women whose tumours had spread beyond the breast there was a significant decrease in risk with increasing dose in women who stopped use more than 10 years previously (figure 11c) but for women with localised disease the patterns were less pronounced and not statistically significant (figure 11b). These results relate to dose in the preparation last used, but broadly similar results were obtained for dose in the preparation first used and that used for the longest time.⁶⁶

Hormonal contraceptives containing progestagens only have not been widely used: oral progestagen-only preparations had been used by only 0.8% of the study population and injectable progestagens by only 1.5%.** The amount of information available was limited, but the results were broadly similar to those found for combined oral contraceptives, with some evidence of an increase in risk for use in the previous 5 years (relative risk 117 [SD=0.09], p=0.06, for oral preparations; 1.17 [SD=0.13], NS, for injectable progestagens) but no evidence of an increase in risk 10 or more years after stopping use (0.99 [SD=0.13], NS, for oral preparations; 0.94 [SD=0.13], NS, for injectable preparations). There were no apparent residual effects of duration of use or age at first use, but the numbers are too small to exclude such effects with any certainty.66

Discussion

This review of 54 studies, conducted in 25 countries, provides strong evidence for two main conclusions. First, while women are taking combined oral contraceptives and in the 10 years after they stop there is a small but definite increase in the risk of having breast cancer diagnosed. Second, this excess risk does not persist and there is no evidence of an increased risk of breast cancer 10 or more years after cessation of use (figure 12). Furthermore, the cancers diagnosed in women who have ever used oral contraceptives are less likely to have spread beyond the breast than those diagnosed in women who have never used oral contraceptives (figures 8–10). Before we consider the implications of these findings, their reliability and consistency are discussed.

Combining results from many studies

Because the 54 studies included here were of varied design and were carried out among women with different baseline risks of breast cancer in different settings, the relative risks associated with the use of oral contraceptives might have been expected to differ substantially between the study designs and between the individual studies. However, after recency of use was taken into account there was no pronounced variability between studies or study designs (figure 7) or between women with different background risks of breast cancer (figures 5 and 6).

Combining results from many studies has the obvious advantage of reducing random errors. Furthermore, because chance alone would make some studies suggest one conclusion and others suggest another conclusion,



Figure 12: Relative risk of breast cancer by time since last use of combined oral contraceptives

Relative risk (given with 95% CI) relative to never-users, stratified by study, age at diagnosis, parity, age at first birth, and age at which risk of conception ceased.

systematic analysis of the worldwide evidence reduces biases that can be produced by undue emphasis on particular studies with extreme results. Although the 54 studies included here were of varied size, no single study was so large as to dominate the overall results.

The data presented here represent about 90% of the worldwide epidemiological evidence on breast cancer risk and use of hormonal contraceptives. What is known about the 12 studies for which data were not included suggests that their results would have been consistent with the main findings. The pooled estimate of the relative risk of everuse of oral contraceptives compared with never-use from those studies⁵⁴⁻⁶⁵ was 1.07 (SD 0.04), which is identical to the estimate of 1.07 found for the data included (figure 1). Five of these studies^{54,57,59,62,65} published data on recent use of oral contraceptives, and the pooled estimate of the relative risk associated with current use or recent use (usually representing use in the last 3 years) was 1.16 (SD 0.11) which again resembles our estimate of 1.16 for recent users (figure 7a). No omitted study reported an increase in breast cancer many years after cessation of oral contraceptive use-in fact, seven54-59,63 were among the earliest studies ever done, and so could not have produced much evidence of any long-term effect to modify the findings reported here for past users. The main results are therefore unlikely to be materially affected by the omission of about 10% of the epidemiological evidence.

Bias, confounding, and chance

As well as the biases that could be caused by undue emphasis on particular studies, selective emphasis on particular subgroups can also introduce bias. Despite the large amount of information available, some untrustworthy irregularities inevitably emerge when data are subdivided in many ways. Nevertheless, it is necessary to divide the data into many subgroups, as has been done here, to examine which patterns of use are associated with risk, and how that risk varies with age, family history, and so on. This report contains some 400 relative risk estimates and their respective confidence intervals. A few apparently heterogeneous findings are observed but it is important to bear in mind that at least part of this apparent variation in risk between subgroups is likely to be due to chance.

Biases can also be introduced if there is differential reporting of oral contraceptive use by cases and controls. The reporting of very short durations of use is a potential source of bias, because a quarter of the ever-users were reported as having used oral contraceptives for less than a year and the proportion of such users varied substantially from one study to another.66 Even a slight tendency for short-duration use to be reported in different ways by cases and controls could bias the results; to assess the potential relevance of this bias, the main analyses were repeated with ever-users defined as women with durations of use of more than a year.⁶⁶ The main conclusions about the relation of breast cancer with respect to time since last use were not altered. There was, however, some suggestion that there may be slight differences in the reporting of brief use at young ages that ceased long ago. Another potential bias is that women who have used oral contraceptives may have their cancer detected earlier than women who have never used oral contraceptives (discussed later).

To minimise the potential for confounding, all analyses were simultaneously stratified for study, age at diagnosis in single years, parity, and, where appropriate, the age a woman was when her first child was born, and the age when her risk of conception ceased. This fine stratification means that no direct comparisons were made between women in one study and women in another and that the contraceptive history of a woman with breast cancer is compared only with that of control women in the same study who were exactly the same age as her and had a similar reproductive history. Although the stratification is fine enough to avoid any material confounding by these factors, it was not excessively fine, since the standard deviations of the main risk estimates are still small. Adjustment for other factors did not alter the associations described here.66

Since the various measures of the timing of exposure to oral contraceptives are highly correlated, failure to stratify by time since last use and age at first use can confound the associations with other related exposures.⁶⁶ For example, duration of oral contraceptive use in young women is highly correlated with time since last use and age at first use, and analyses that do not stratify by those factors can produce apparent associations between breast cancer risk and duration of use.

Excess risk in recent users

The increased risk of breast cancer being diagnosed among current users and among women whose use ceased 1-4 years previously is each based on large numbers and is highly statistically significant. These findings were seen consistently between studies, although few studies showed a significant excess in their own right (figure 7a). The relative risk declined with time after cessation of use and was still slightly increased 5–9 years after cessation of use (figure 12). The excess risk in recent users was largely associated with tumours localised to the breast (figure 10).

Few factors appeared to modify the relative risks associated with recent use of oral contraceptives, despite the large number of possibilities considered.⁶⁶ For example, there was no strong evidence of variation in risk with duration of oral contraceptive use, or with respect to family history of breast cancer, ethnic origin, age at menarche, height, weight, menopausal status, or alcohol use. The only factor identified that had much effect on the relative risk associated with recent use of oral contraceptives was age at first use (figure 3b). For recent users the relative risks were greater for those who began before age 20 than for those who began at later ages (figure 3b) and tended to decline with increasing age at diagnosis (figure 4).

Overall, the risk of breast cancer in recent users is not significantly related to the dose or type of hormone within the hormonal contraceptive used.⁶⁶ The limited information available for hormonal contraceptives containing progestagens alone suggests that use of oral or injectable progestagen-only preparations might also involve a small increase in breast cancer being diagnosed in recent users.

No adverse effect in the long term

There is no evidence of an excess risk of breast cancer 10 or more years after cessation of use overall (relative risk 1.01 [SD 0.02]). The lack of an increased risk 10 or more years after stopping is seen fairly consistently in individual studies and in most subgroups of women. The cancers diagnosed 10 or more years after cessation of use are, however, slightly less likely to have spread beyond the breast than the cancers diagnosed in never-users (figure 10).

Although the absence of an increase in breast cancer risk 10 or more years after cessation of oral contraceptive use is reliably established, the available information is still somewhat limited. Oral contraceptives have been widely used only since the 1960s and most of the cancers included in these analyses were diagnosed during the 1980s. Thus there is still little information beyond 20 years after cessation of use. Moreover, most women who stopped use 10 or more years ago had used oral contraceptives only for short periods (figure 3a) and tended to have used medium-dose or high-dose preparations (figure 11).

Possible explanations of findings

The relations observed here between cancer risk and exposure are unusual, since the risk increases soon after first exposure, does not increase with duration of exposure, and returns to normal 10 years after cessation of exposure. Such a pattern seems incompatible with a genotoxic effect. An increased risk in recent users is, perhaps, compatible with the classic concept of the promotion of tumours that have already been initiated. The deficits in risk seen in certain groups 10 or more years after cessation of exposure, if confirmed, might be indicative of analogous effects of hormonal contraceptives and of childbearing on breast cancer risk.

The finding that the breast cancers in women who had used oral contraceptives were less advanced clinically than those in never-users raises the possibility that users of oral contraceptives may have had their cancers diagnosed earlier in the development of the disease than would otherwise have happened. If this were so, the implication from these data is that women who have used oral contraceptives continue to have their cancers diagnosed earlier than never-users even many years after use ceases because the relative excess of localised tumours is similar in current and past users and does not vary significantly with time since last use.⁴⁶ Alternatively, oral contraceptives might affect the rate of growth of tumours and their tendency to metastasise. It is not possible to infer from

Vol 347 • June 22, 1996



Figure 13: Estimated cumulative number of breast cancers diagnosed in never-users and in women who used oral contraceptives at various ages

Estimated numbers for 10 000 women in Europe or North America; details of calculations are given elsewhere.^{se} Note: the estimated numbers for ever-users and never-users are so similar in some age ranges that they overlap almost entirely.

these data whether the patterns of risk observed are due to an earlier diagnosis of breast cancer in ever-users, the biological effects of hormonal contraceptives, or a combination of both factors. Further information is needed on whether women who have used oral contraceptives are more likely to have their cancers detected earlier, how long the deficit of advanced disease persists, its relation to hormone dose, and whether there is differential survival in ever-users and never-users.

There is no clear explanation for the finding that the relative risk associated with current use or use that ceased in the previous 5 years is higher for women who began use before age 20 than after that age. This finding could reflect a comparatively greater effect of the artificial preparations before adult hormone secretion patterns are fully established. Alternatively, it could be partly due to differential reporting of use at young ages by cases and controls, chance, or a combination of reasons. The available data for use beginning before age 20 indicate that there is no substantial increase of breast cancer risk in this subgroup more than 5 years after cessation of use, but virtually all the existing information relates to women younger than 45. In the next decade women who began use as teenagers will reach their late 40s and early 50s, when breast cancer is more common. When the new data on the long-term effects of early use become available it will be necessary to re-examine the worldwide evidence.

Calculated numbers of breast cancers diagnosed in ever-users compared with never-users

Even though it is not possible to infer from these data whether the findings described here are due to the earlier diagnosis of breast cancer among ever-users, the biological effects of hormonal contraceptives, or a combination of reasons, the approximate number of cancers that would be diagnosed in women who have used oral contraceptives can be calculated. Combining the estimates of relative risk by time since last use suggested by these analyses with incidence rates of breast cancer in various populations, calculations were made of the cumulative number of breast cancers diagnosed in women who had used oral contraceptives at various ages for various durations.⁶⁰ Figure 13 shows, as an example, the calculated cumulative numbers of cancers diagnosed in 10 000 women in Europe or North America who used oral contraceptives from age 16 to 19, from age 20 to 24, and from age 25 to 29, compared with women who had never used them. There is a small excess in the estimated number of cancers diagnosed in the period from starting oral contraceptive use up to 10 years after stopping, but by 20 years after



Figure 14: Estimated cumulative number of breast cancers diagnosed in never-users and in women who used oral contraceptives from age 25 to 29, according to extent of tumour spread

Estimated numbers for 10 000 women in Europe or North America; details of calculations are given elsewhere.⁶⁵

1724

stopping there is no significant difference between everusers and never-users in the cumulative numbers diagnosed. For women in developing countries the incidence of breast cancer is lower than in Europe or North America and thus, even with the same relative risks, the differences between the calculated results for everusers and never-users in the cumulative numbers of breast cancers diagnosed are even smaller than those shown in figure 13.⁶⁶

It can be seen in figure 13 how rare breast cancer is among women in their 20s and 30s compared with older ages and that the excess number of cancers diagnosed in current and recent users of oral contraceptives is small in relation to the cumulative risk of breast cancer. In particular, the comparatively higher relative risk in current or recent users who began use before age 20 (figure 3b) which was used to calculate the cumulative incidence associated with oral contraceptive use from age 16 to 19 in figure 13, act at an age when the background incidence of breast cancer is low.

The calculated cumulative number of breast cancers diagnosed in 10000 women in Europe or North America in the period between starting use and 10 years after stopping is approximately 4.5 for use from age 16 to 19 compared with 4.0 in 10000 never-users of the same age over the same period; 17.5 compared with 16.0 for use from age 20 to 24; 48.7 compared with 44.0 for use from age 25 to 29; 110 compared with 100 for use from age 30 to 34; 180 compared with 160 for use from age 35 to 39; and 260 compared with 230 for use from age 40 to 44. These numbers correspond to cumulative excesses of 0.5 (SD 0·1), 1·5 (0·4), 4·7 (1·0), 11·1 (2·1), 21·0 (3·6), and 32.0 (5.0) per 10000, respectively.66 Thus for a given duration of use, earlier use does not not lead to a greater number of cancers being diagnosed. Indeed, the calculated cumulative excess increases with increasing age at last use, and, as shown elsewhere,66 for a given age at last use the excess is little affected by a woman's prior duration of oral contraceptive use. In addition, as illustrated in figure 14, virtually all the excess cancers diagnosed up to 10 years after cessation of use are localised to the breast, and there is little or no evidence of a cumulative excess of tumours that had spread beyond the breast.66

The calculated cumulative number of breast cancers diagnosed up to 20 years after cessation of oral contraceptive use is largely influenced by the results for use that stopped between 10 and 20 years ago, because breast cancer incidence increases rapidly with age. There is no excess risk of having breast cancer diagnosed between 10 and 20 years after stopping and, indeed there may be a slight deficit in the number of breast cancers diagnosed during that period, which could offset some of the excess diagnosed up to 10 years after stopping.66 Furthermore, the cancers diagnosed between 10 and 20 years after cessation of use are less likely to have spread beyond the breast than are the cancers diagnosed in neverusers. Hence, 20 years after cessation of oral contraceptive use the difference between ever-users and never-users is not so much in the cumulative number of breast cancers diagnosed, but in the clinical presentation of the tumours. This is illustrated in figure 14 for women who used oral contraceptives from age 25 to 29, where it can be seen that up to 20 years after cessation of use (ie, by age 50) there is a small excess of localised cancers and a small deficit of cancers that have spread beyond the breast but there is little difference in the total number of breast cancers diagnosed. Tumours that are localised to the breast are associated with a better survival than tumours that have spread beyond it,⁷⁰ but without follow-up information on the women with breast cancer it is not possible to be sure whether oral contraceptive use increases, decreases, or has no effect on cumulative mortality from breast cancer.

As yet there is little information about use that ceased more than 20 years ago. Consequently, the conclusion from these calculations can be only that up to 20 years after cessation of use there is little difference in the cumulative incidence of breast cancer between women who have used and have not used oral contraceptives.

Implications

For women using, or contemplating the use of, oral contraceptives there is a small increase in the risk of having breast cancer diagnosed while taking oral contraceptives and during the 10 years thereafter. The older women are at last use, the larger the number of excess cancers diagnosed during this period is likely to be, although the additional cancers diagnosed are mainly ones that are localised to the breast.

For women who have used hormonal contraceptives in the past these results indicate that 10 years after cessation of use there is little or no increase in the risk of having breast cancer diagnosed, and that the cancers diagnosed are less advanced clinically than the cancers diagnosed in women who have never used oral contraceptives.

Collaborators

Members of analysis and writing committee indicated by *.

American Cancer Society: E E Calle, C W Heath Jr, H L Miracle-McMahill; Atlanta, Emory University: R J Coates, J M Liff; Aviano Cancer Center, Pordenone: S Franceschi, R Talamini; Bangkok, Mahidol University: N Chantarakul, S Koetsawang, D Rachawat; Breast Tumor Collaboration Study, Johns Hopkins University: A Morabia, L Schuman, W Stewart, M Szklo; Brisbane, University of Queensland: C Bain, F Schofield, V Siskind; British Colombia Cancer Agency: P Band, A J Coldman, R P Gallagher, T G Hislop, P Yang; Cambridge, MRC Biostatistics Unit: S W Duffy; Cancer Research Center, University of Hawaii: L M Kolonel, A M Y Nomura; Centers for Disease Control and Prevention: M W Oberle, H W Ory, H B Peterson, H G Wilson, P A Wingo; Central Institute of Cancer Research, German Democratic Repulic: K Ebeling, D Kunde, P Nishan; Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School: G Colditz for Nurses Health Study Research Group; Chiang Mai University: N Martin, T Pardthaisong, S Silpisornkosol, C Theetranont; Chulalongkorn University: B Boosiri, S Chutivongse, P Jimakorn, P Virutamasen, C Wongsrichanalai; CSIRO Division of Human Nutrition, Adelaide: A J McMichael, T Rohan; Danish Cancer Society: M Ewertz; Dunedin, University of Otago: C Paul, D C G Skegg; European Institute of Oncology: P Boyle, M Evstifeeva; Fred Hutchinson Cancer Research Center: J R Daling, K Malone, E A Noonan, J L Stanford, D B Thomas, N S Weiss, E White; French Multicentre Breast Study, INSERM: N Andrieu, A Brêmond, F Clavel, B Gairard, J Lansac, L Piana, R Renaud; Holly Lodge: SRP Fine; Hospital General de Mexico: H R Cuevas, P Ontiveros, A Palet, S B Salazar; Hospital Universitario: N Aristizabel, A Cuadros; INSERM, Institut Gustave-Roussey, Villejuif: A Bachelot, M G Lê; Institute of Cancer Research, Sutton: J Deacon, J Peto, C N Taylor; Israel Chaim Sheba Medical Center: E Alfandary, B Modan, E Ron; Kaiser Permanente, California: G D Friedman, R A Hiatt; Leeds, ICRF Genetic Epidemiology Laboratory: T Bishop; Ljubljana, Institute of Oncology: J Kosmelj, M Primic-Zakelj, B Ravnihar, J Stare; Loma Linda University: W L Beeson, G Fraser; London, Imperial Cancer Research Fund: D S Allen, R D Bulbrook, J Cuzick, I S Fentiman, J L Hayward, D Y Wang; Long Island Breast Cancer Study: R L Hanson, M C Leske, M C Mahoney, P C Nasca, A O Varma, A L Weinstein; Lund, University Hospital: T R Moller, H Olsson, J Ranstam; Maastricht, University of Limburg: R A Goldbohm, P A van den Brandt; Manila, University of Philippines: R A Apelo, J Baens, J R de la Cruz, B Javier, L B Lacaya, C A Ngelangel; Milan, Istituto "Mario Negri": C La Vecchia, E Negri; Milan; Istituto Nazionale Tumori, Divisione di Statistica Medica e Biometria: E Marubini; Milan, Istituto di Statistica Medica e Biometria; M Ferraroni; Montpellier Cancer

Centre & INSERM: M Gerber, S Richardson, C Segala; Nairobi Centre for Research in Reproduction: D Gatei, P Kenya, A Kungu, J G Mati; National Cancer Institute, Bethesda: L A Brinton, R Hoover, C Schairer; National Institute of Child Health and Human Development, Bethesda: R Spirtas; National University of Singapore: H P Lee; Netherlands Cancer Institute: M A Rookus, F E van Leeuwen for the Netherlands Oral Contraceptives and Breast Cancer Study Group; New Jersey State Department of Health; J A Schoenberg; New York, Columbia University School of Public Health: M D Gammon: Ontario Cancer Treatment & Research Foundation: E A Clarke; Oxford, Department of Public Health & Primary Care: L Jones, K McPherson, A Neil, M Vessey, D Yeates; Oxford, ICRF Cancer Epidemiology Unit (Secretariat): V Beral*, D Bull*, B Crossley, C Hermon, S Jones, T Key, C Lewis, G Reeves*, P Smith Oxford, ICRF/MRC/BHF Clinical Trial Service Unit & Epidemilogical Studies Unit: R Collins, R Doll, R Peto*; Royal College of General Practitioners Oral Contraception Study: P Hannaford, C Kay; San Jose, University of Costa Rica: L Rosero-Bixby; Shanghai Cancer Institute: Y-T Gao, J-M Yuan; Shanghai Institute of Planned Parenthood Research: H Y Wei, T Yun, C Zhiheng, Sidney, Department of Public Health: G Berry, J Cooper Booth, T Jelihovsky, R MacLennan, R Shearman; Tianjin Cancer Institute: Q-S Wang; Toronto, Department of Preventive Medicine & Biostatistics: C J Baines, A B Miller, C Wall; Tromso University: E Lund, H Stalsberg; University of Chile: A Dabancens, L Martinez, R Molina, O Salas; University of Edinburgh: F E Alexander; University of North Carolina at Chapel Hill, School of Public Health: B S Hulka; University of Nottingham: CED Chilvers; University of Southern California: L Bernstein, R W Haile, A Paganini-Hill, M C Pike, R K Ross, G Ursin, M C Yu; University of Uppsala: H O Adami, R Bergstrom; University of Wisconsin Comprehensive Cancer Center: M P Longnecker, P Newcomb for the 4 State Study; World Health Organization, UNDP/UNFPA/WHO/World Bank Special Programme of Research Development and Training in Human Reproduction: T M N Farley, S Holck, O Meirik.

Tens of thousands of women with breast cancer and without breast cancer throughout the world have contributed to this research. This review would not have been possible without their help or without the careful collection and checking of data at each of the collaborating institutions. Central pooling and analysis was supported by the Imperial Cancer Research Fund.

References

- 1 Kleinman EL, ed. Hormonal contraception. London: IPPF Medical Publications, 1990.
- 2 Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980; 243: 1635-39.
- 3 Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: possible modyfying effect of formulation and age at use. *Lancet* 1983; ii: 926–30.
- 4 Vessey M, Baron J, Doll R, McPherson K, Yeates D. Oral contraceptives and breast cancer: final report of an epidemiologic study. Br J Cancer 1983 47: 455-62.
- 5 Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. *Cancer* 1984; 54: 139–44.
- 6 Lê MG, Bachelot A, Doyon F, Kramer A, Hill C. Oral contraceptive use and breast cancer or cervical cancer: preliminary results of a French case-control study. In: Wolff JP, Scott JS, eds. Hormones and sexual factors in human cancer aetiology. Amsterdam: Elsevier Science Publishers, 1984.
- 7 Talamini R, La Vecchia C, Franceschi S, et al. Reproductive and hormonal factors and breast cancer in a Northern Italian population. Int J Epidemiol 1985; 14: 70–74.
- 8 Hislop TG, Coldman AJ, Elwood JM, Brauer G, Kan L. Childhood and recent eating patterns and risk of breast cancer. *Cancer Detection Prevention* 1986; 9: 47–58.
- 9 Meirik O, Lund E, Adami HO, Berrgstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and breast cancer in young women: a joint national case-control study in Sweden and Norway. *Lancet* 1986; ii: 650–54.
- 10 Nomura AMY, Kolonel LN, Hirohata T, Lee J. The association of replacement estrogens with breast cancer. Int J Cancer 1986; 37: 49–53.
- 11 Alexander FE, Roberts MM, Huggins A. Risk factors for breast cancer with applications to selection for the prevelance screen. J Epidemiol Commun Health 1987; 41: 101–06.
- 12 Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whately AS, Rovira EZ. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 1987; 79: 1247–54.
- 13 McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M. Early oral contraceptive use and breast cancer: results of another casecontrol study. Br J Cancer 1987; 56: 653–60.
- 14 Wang DY, De Stavola BL, Bulbrook RD, et al. The relationship

1726

between blood prolactin levels and risk of breast cancer in premenopausal women. Eur J Clin Oncol 1987; 23: 1541-48.

- 15 Kay CR, Hannaford PC. Breast cancer and the pill—a futher report from the Royal College of General Practitioners' Oral Contraception Study. Br J Cancer 1988; 58: 675–80.
- 16 Ravnihar B, Primic-Zakelj M, Kosmelj K, Stare J. A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. *Neoplasma* 1988; 35: 109-21.
- 17 Rohan TE, McMichael AJ. Oral contraceptive agents and breast cancer: a population-based case-control study. *Med J Aust* 1988; 149: 520-26.
- 18 Yuan J-M, Yu MC, Ross RK, Gao Y-T, Henderson BE. Risk factors for breast cancer in Chinese women in Shanghai. *Cancer Res* 1988; 48: 1949–53.
- 19 Mills PK, Beeson WL, Phillips RL, Fraser GE, Prospective study of exogenous hormone use and breast cancer in seventh-day adventists. *Cancer* 1989; 64: 591–97.
- 20 Marubini E, Decarli A, Costa A, et al. The relationship of dietary intake and serum levels of retinol and beta-carotene with breast cancer: results of a case-control study. *Cancer* 1988; 61: 173–80.
- 21 Olsson H, Moller TR, Ranstam J. Early oral contraceptive use and cancer among premenopausal women: final report from a study in southern Sweden. *J Natl Cancer Inst* 1989; 81: 1000–04.
- 22 Romieu I, Willett W, Colditz G, et al. Prospective study of oral contraceptive use and the risk of breast cancer in women. *J Natl Cancer Inst* 1989; **81:** 1313–21.
- 23 Siskind V, Schofield F, Rice D, Bain C. Breast cancer and breast feeding: results from an Australian case-control study. Am J Epidemiol 1989: 130: 229–36.
- 24 Stanford JL, Brinton LA, Hoover RN. Oral contraceptives and breast cancer: results from an expanded case-control study. Br J Cancer 1989; 60: 375–81.
- 25 UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. *Lancet* 1989; i: 873–82.
- 26 Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989; 59: 613–17.
- 27 Bernstein L, Pike MC, Krailo M, Henderson BE. Update of the Los Angeles study of oral contraceptives and breast cancer: 1981 and 1983. In: Mann RD, ed. Oral contraceptives and breast cancer. Park Ridge: Parthenon Publishing, 1990: 169–81.
- 28 Paul C, Skegg DCG, Spears GFS. Oral; contraceptives and risk of breast cancer. Int J Cancer 1990; 46: 366-73.
- 29 Schildkraut JM, Hulka BS, Wilkinson WE. Oral contraceptives and breast cancer: a case-control study with hospital and community controls. *Obstet Gynecol* 1990; 76: 395–402.
- 30 WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and combined oral contraceptives: results from a multinational study. Br J Cancer 1990; 61: 110–19.
- 31 Clavel F, Andricu N, Gairard B, et al. Oral contraceptives and breast cancer: a French case-control study. Int J Epidemiol 1991; 20: 32–38.
- 32 Segala C, Gerber M, Richardson S. The pattern of risk factors for breast cancer in a Southern France population: interest for a stratified analysis by age at diagnosis. Br J Cancer 1991; 64: 919-25.
- 33 Weinstein AL, Mahoney MC, Nasca PC, Leske MC, Varma AO. Breast cancer risk and oral contraceptive use: results from a large casecontrol study. *Epidemiology* 1991; 2: 353–58.
- 34 Wingo PA., Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P. Agespecific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991; 78: 161–70.
- 35 Ewertz M. Oral contraceptives and breast cancer risk in Denmark. Eur *J Cancer* 1992; **28A:** 1176–81.
- 36 Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Risk factors for breast cancer by age and menopausal status: a case-control study in Singapore. Cancer, Causes and Control 1992; 3: 313-22.
- 37 Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Scrteening Study I, breast cancer detection and death rates among women aged 40-49 years. *Can Med Assoc* J 1992; 147: 1459-76.
- 38 Rosenberg L, Palmer JR, Clarke EA, Shapiro S. A case-control study of the risk of breast cancer in relation to oral contraceptive use. *Am J Epidemiol* 1992; 136: 1437–44.
- 39 Ursin G, Aragaki CC, Paganini-Hill A, Siemiatycki J, Thompson WD, Haile RW. Oral contraceptives and premenopausal bilateral breast cancer: a case-control study. *Epidemiology* 1992; 3: 414–19.
- 40 Wang Q-S, Ross RK, Yu MC, Ning J-P, Henderson BE, Kimm HT. A case-control study of breast cancer in Tianjin, China. Cancer Epidemiol, Biomarkers Prevent 1992; 1: 435–39.
- 41 Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Non-contraceptive hormone use and risk of breast cancer. *Cancer Causes Control* 1992; **3:** 475–79.
- 42 Calle EE, Martin LM, Thun MJ, Miracle HL, Heath CW Jr. Family history, age, and risk of fatal breast cancer. Am J Epidemiol 1993; 138: 675–81.

- 43 Ngelangel CA, Lacaya LB, Cordero C, Laudico AV. Risk factors for breast cancer among Filipino women. *Phil J Intern Med* 1994; 32: 231-36.
- 44 Morabia A, Szklo M, Stewart W, Schuman L, Thomas DB. Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighbourhood controls. *Prevent Med* 1993; 22: 178–86.
- 45 Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C. Oral contraceptives and breast cancer in Northern Italy: final report from a case-control study. Br J Cancer 1993; 68: 68–71.
- 46 Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormones and the risk of postmenopausal breast cancer: results from the Netherlands cohort study. *Cancer Causes Control* 1995; 6: 416-24.
- 47 Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med 1994; 330: 81-87.
- 48 Primic-Zakelj M, Evstifeeva T, Ravnihar B, Boyle P. Breast cancer risk and oral contraceptive use in Slovenian women aged 25 to 54. Int J Cancer 1995; 62: 414_20.
- 49 Rookus MA, van Leeuwen FE for the Netherlands Oral Contraceptives and Breast Cancer Study Group. Oral contraceptives and risk of breast cancer in women aged 20–54 years. *Lancet* 1994; 344: 844–51.
- 50 White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young US women in relation to oral contraceptive use. J Natl Cancer Inst 1994; 86: 505-14.
- 51 La Vecchia C, Negri E, Franceschi S, et al. Oral contraceptives and breast cancer: a cooperative Italian study. Int J Cancer 1995; 60: 163–67.
- 52 Rossing MA, Stanford JL, Weiss NS, Habel I.A. Oral contraceptive use and risk of breast cancer in middle-aged women. Am J Epidemiol (in press).
- 53 Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. *J Natl Cancer Inst* 1995; 87: 827-35.
- 54 Paffenbarger RS, Fasal E, Simmons ME, Kampert JB. Cancer risk as related to use of oral contraceptives during fertile years. *Cancer* 1977; **39**: 1887–91.
- 55 Sartwell PE, Arthes FG, Tonascia JA. Exogenous hormones, reproductive history and breast cancer. *J Natl Cancer Inst* 1977; 59: 1589–92.
- 56 Kelsey JL, Holford TR, White C, Mayer ES, Kilty SE, Acheson RM. Oral contraceptives and breast disease: an epidemiological study. *Am J Epidemiol* 1978; 107: 236–44.
- 57 Ravnihar B, Seigel DG, Lindtner J. An epidemiologic study of breast

cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979; 15: 395-405.

- 58 Ramcharan S, Pellegrin FA, Ray RM, Hsu J-P. The Walnut Creek contraceptive drug study: a prospective study of the side effects of oral cont raceptives. In: NIH publication no 81–564. Centre for Population Research Monograph. Volume III. Bethesda: NIH, 1981: 43–69.
- 59 Janerich DT, Polednak AP, Glebartis DM, Lawrence CE. Breast cancer and oral contraceptive use: a case-control study. J Chron Dis 1983 36: 639–46.
- 60 Brownson RC, Blackwell CW, Pearson DK, Reynolds RD, Richens JW, Papermaster BW. Risk of breast cancer in relation to cigarette smoking. Arch Intern Med 1988; 148: 140–44.
- 61 Jick SS, Walker AM, Stergachis A, Jick H. Oral contraceptives and breast cancer. Br J Cancer 1989; 59: 618-21.
- 62 Harris RE, Zang EA, Eynder EL. Oral contraceptives and breast cancer risk: a case-control study. Im J Epidemiol 1990; 19: 240-46.
- 63 Wynder EL, MacCornack FA, Stellman SD. The epidemiology of breast cancer in 785 United States caucasian women. *Cancer* 1978; 41: 2341–54.
- 64 Harris NV, Weiss NS, Francis AM, Polissar L. Breast cancer in relation to patterns of oral contraceptive use. Am J Epidemiol 1982; 116: 643–51.
- 65 Rosenberg L, Palmer JR, Rao RS, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996; 143: 25–37.
- 66 Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. *Contraception* (in press).
- 67 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep* 1966; **50:** 163–70.
- 68 Peto Rm Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: I introduction and design. Br J Cancer 1976; 34: 585-612.
- 69 Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II, analysis and examples. Br J Cancer 1977; 35: 1–39.
- 70 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. *Lancet* 1992; **339**: 1–15.
- 71 Easton DF, Peto J, Babiker AGAG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. *Stat Med* 1991; 10: 1025–35.